Alexander J Denner has been appointed to The Medicines Company Board of Directors. Denner will serve as a class III director, with a term expiring at the company’s 2018 Annual Meeting of Stockholders. He will also serve on the Company’s Nominating and Corporate Governance Committee.
With Denner’s appointment—effective from February 2, 2016—the company’s Board of Directors is comprised of 11 directors, ten of whom are independent.
Denner has worked with a number of investment firms, and with biopharmaceutical companies, Biogen and ARIAD Pharmaceuticals. He has previously worked with life sciences companies, Amylin Pharmaceuticals, VIVUS, and others. Denner received his bachelor of science degree from the Massachusetts Institute of Technology, Cambridge, USA, and his master of science, master of philosophy and doctor of philosophy degrees from Yale University, New Haven, USA.
“We are very pleased to have Alex join the Board,” says Fredric Eshelman, chairman of the Board. “His broad range of experience as a healthcare investor and director, as well as in overseeing the operations and Research and development of healthcare companies, will be a tremendous asset to The Medicines Company. We look forward to drawing on Alex’s expertise as we continue to execute on our plan.”
“Alex has been supportive of The Medicines Company for many years, and I am delighted to welcome [him] to the Board,” says Clive Meanwell, chief executive officer. “Alex will no doubt provide valuable insight and guidance as we continue to take decisive actions for the benefit of all shareholders.”
Denner adds, “I am honoured to join the Board of Directors at this exciting time, and I look forward to working with the other members of the Board to unlock shareholder value.”
